Biomatlante Announces the Appointment of its New CEO
Julien Dert named as new CEO of Biomatlante, Chantal Gobin continues as Chairman of the Board
“I am extremely honored that Biomatlante’s shareholders, especially the founders Chantal Gobin and Guy Daculsi, have put their confidence in me”
NANTES, FRANCE (PRWEB) FEBRUARY 01, 2019
Biomatlante, a world leader in synthetic bone regeneration technologies, is pleased to announce the appointment of its new CEO, Julien Dert, being effective on February 1st, 2019.
Graduated from ICN Business School, Julien has 25 years of international experience in finance and management, in which more than 12 years in the Medical Device industry. Chief Financial Officer of Biomatlante and member of its Management Committee since 2009, he has worked closely with Chantal Gobin in the development of the company, preserving its capacity of innovation in a challenging competitive and regulatory environment.
“I am extremely honored that Biomatlante’s shareholders, especially the founders Chantal Gobin and Guy Daculsi, have put their confidence in me. Chantal and Guy are true visionaries, whose passion for the company will serve as a model for the future,” says Julien Dert. “I know Biomatlante very well, and I know I can count on a dynamic and dedicated team to continue to bring the best therapeutic solutions to patients. I am thrilled to have this opportunity to shepherd Biomatlante’s continued growth in innovative bone regenerative technologies.”
“Creating a company is a permanent commitment, we have to ensure its development, its sustainability, being surrounded by people with the same values. It is therefore with confidence and pride that I convey the management to Julien,” says Chantal Gobin, Chairman of Biomatlante’s Board. “I know he will preserve the DNA of Biomatlante, considering the respect of the human person, the loyalty, the thoroughness, the adhesion to Research and Development, the insurance of a quality policy respecting the regulatory requirements of the medical devices, with the aim of preserving the safety of the patients. As Chairman, it is a great pleasure to support Julien in his new CEO position”.